Dr Vanessa Bonazzi
This person does not currently hold a position at QUT.
Personal details
Discipline
Medical Biochemistry and Metabolomics, Medical Microbiology
Field of Research code, Australian and New Zealand Standard Research Classification (ANZSRC), 2008
Qualifications
- PhD (Institut Curie Universite Paris VII)
Publications
- Packer L, Geng X, Bonazzi V, Ju R, Mahon C, Cummings M, Stephenson S, Pollock P, (2017) PI3K inhibitors synergize with FGFR inhibitors to enhance antitumor responses in FGFR2-mutant endometrial cancers, Molecular Cancer Therapeutics, 16 (4) p637
- Stark M, Tom L, Boyle G, Bonazzi V, Soyer H, Herington A, Pollock P, Hayward N, (2016) The 'Melanoma-enriched' microRNA miR-4731-5p acts as a tumour suppressor, OncoTarget, 7 (31) p49677
- Stark M, Bonazzi V, Boyle G, Palmer J, Symmons J, Lanagan C, Schmidt C, Herington A, Ballotti R, Pollock P, Hayward N, (2015) miR-514a regulates the tumour suppressor NF1 and modulates BRAFi sensitivity in melanoma, OncoTarget, 6 (19) p17753
- Stark M, Woods S, Gartside M, Bonazzi V, Dutton-Regester K, Aoude L, Chow D, Sereduk C, Niemi N, Tang N, Ellis J, Reid J, Zismann V, Tyagi S, Muzny D, Newsham I, Wu Y, Palmer J, Pollak T, Youngkin D, Brooks B, Lanagan C, Schmidt C, Kobe B, MacKeigan J, Yin H, Brown K, Gibbs R, Trent J, Hayward N, (2012) Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing, Nature Genetics, 44 (2) p165
- Boyle G, Woods S, Bonazzi V, Stark M, Hacker E, Aoude L, Dutton-Regester K, Cook A, Sturm R, Hayward N, (2011) Melanoma cell invasiveness is regulated by miR-211 suppression of the BRN2 transcription factor, Pigment Cell and Melanoma Research, 24 (3) p525
- Dry J, Pavey S, Pratilas C, Harbron C, Runswick S, Hodgson D, Chresta C, McCormack R, Byrne N, Cockerill M, Graham A, Beran G, Cassidy A, Haggerty C, Brown H, Ellison G, Dering J, Taylor B, Stark M, Bonazzi V, Ravishankar S, Packer L, Xing F, Solit D, Finn R, Rosen N, Hayward N, French T, Smith P, (2010) Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244), Cancer Research, 70 (6) p2264
QUT ePrints
To find publications by Vanessa, visit QUT ePrints, the University's research repository.